# Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

> **NCT00937482** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 18 (actual)

## Conditions studied

- Male Breast Cancer
- Stage IV Breast Cancer
- Stage IV Melanoma
- Stage IV Non-small Cell Lung Cancer
- Stage IV Renal Cell Cancer
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer
- Tumors Metastatic to Brain

## Interventions

- **DRUG:** cediranib maleate
- **RADIATION:** whole-brain radiation therapy

## Key facts

- **NCT ID:** NCT00937482
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Administratively complete.
- **Last updated:** 2013-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937482, "Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00937482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*